The FDA expanded the Pfizer/BioNTech RNA COVID-19 vaccine to 12-15 year olds yesterday.
🔵Excellent protection (100% = 0 cases versus 18)
🔵Excellent safety (On to younger children already)
🔵Better antibodies than adults
Also bodes well for other COVID vaccines in kids!🧵
FDA CBER head Dr. Marks:"It was a relatively straightforward decision. The response..was excellent and in fact it was even better, really, in the younger age group than it was in the 16-25 age group. The safety profile was very similar in 12-15-year-olds as in 16-25-year-olds."
Moderna results are out for their booster vaccines!
🔵 Boosting with same vaccine generates good antibodies against variant B.1.351
🔵 Boosting with a B.1.351 vaccine generates even better antibodies
🔵 Safe
🔵 The booster vaccine was made and tested with exceptional speed!
🧵
The reason for excitement about this is that there has been uncertainly for months about vaccine efficacy against B.1.351 (1st seen in South Africa) and similar variants. Since January I have been saying:
Moderna, Pfizer, J&J and other vaccine companies have all stated that they are developing B.1.351 boosters or similar. Today is the first public data on such a vaccine.
Big knowledge gap was will the COVID RNA vaccines work vs B.1.351 and P.1 variants. Now Pfizer protects well vs B.1.351!
🔵 ~75% against infection
🔵 ~97% against severe/fatal disease
Very good news for the rest of 2021 for any countries using Pfizer and Moderna vaccines! 🧵
B.1.351 and P.1 (1st found in South Africa and Brazil) have been the two biggest variants of concern that have a degree of antibody escape. As of this morning (and February), some vaccines (AZ) showed only 11% effectiveness against B.1.351 cases,
and the best clinical trial data was ~50-66% vaccine efficacy against B.1.351 cases (J&J and Novavax), and only data for non-hospitalized cases (because of the size of the studies). Leaving lots of uncertainty.
The Crotty Lab journal club this week was from the Brink lab. Sundling et al.: “Positive selection of IgG+ over IgM+ B cells in the germinal center reaction”. 🧵 @ImmunityCP
Using various mouse models, the authors sought to understand the process by which IgG antibodies come to dominate mature antibody responses.
High-affinity IgG+ germinal center B cells are positively selected over high-affinity IgM+ germinal center (GC) B cells via a process based on antigen receptor constant regions
Oral SARS-CoV-2
I love this paper! Important demonstration of SARS2 infection in the mouth. And outstanding paper on oral biology and immunology relevant for viral infections. I learned so much! 🧵
Outstanding new preprint studying immune memory after COVID-19 for 8 months, assessing memory T & B cells in addition to antibodies. High quality work from the Ahmed, McElrath, @SutharLab , and Wrammert labs! 🧵
Beautiful application of a new power law approach to calculate the trajectory of decay of T & B cell memory as well as antibodies to SARS-CoV-2, which could be well applied here due to the longitudinal study design.
This is consistent with the idea that each immune memory types consists of multiple subcomponents, with some subpopulations having more duration that others.